Vivozon Applies for MFDS IND for Phase 1 Clinical Trial of Drug Addiction Treatment Candidate

원본보기 아이콘

[Asia Economy Reporter Lee Gwan-joo] Vivozon announced on the 13th that it has applied for clinical trial approval (IND) from the Ministry of Food and Drug Safety to conduct a Phase 1 clinical trial in Korea for its second new drug pipeline, 'VVZ-2471.'

VVZ-2471 is an oral new drug candidate that shows analgesic efficacy as well as effectiveness against drug addiction similar to morphine. This clinical trial will be conducted on 78 adult males at Seoul National University Bundang Hospital.

Vivozon filed substance patents for VVZ-2471 in Korea and the United States in July 2020 and January 2022, respectively, and filed a domestic use patent for drug addiction in January 2022.

Through non-clinical efficacy tests conducted with Sungkyunkwan University until last year, the company explained that the therapeutic and preventive effects on morphine addiction were proven, and subsequently, the efficacy of suppressing withdrawal symptoms caused by morphine discontinuation and preventing relapse of addiction were also identified.

Additionally, in non-clinical trials conducted by Naason Science, VVZ-2471 showed anxiety reduction effects comparable to the antipsychotic drug diazepam and depression reduction effects equivalent to the antidepressant fluoxetine, confirming its antidepressant and anti-anxiety effects, the company added.

Lee Doo-hyun, Chairman of Vivozon, said, “VVZ-2471 is suitable for targeting the drug addiction market as it has preventive and therapeutic effects on drug addiction and relapse prevention, while also suppressing withdrawal symptoms and providing analgesic, anti-anxiety, and antidepressant effects. Its value is limitless as it can be expanded to a larger market.”

Meanwhile, Vivozon’s core pipeline, the non-narcotic analgesic Opiranserin (VVZ-149), is currently undergoing Phase 3 clinical trials in Korea and the United States for postoperative pain, with the ultimate goal of completely replacing narcotic analgesics as a postoperative pain treatment.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.